Analysis of U.S. Patent 10,688,094: Scope, Claims, and Patent Landscape
What Does the Patent Cover?
U.S. Patent 10,688,094, granted on June 23, 2020, primarily protects a pharmaceutical compound, its pharmaceutically acceptable salts, and compositions containing these elements. The patent focuses on a novel class of compounds targeting specific molecular pathways, with potential applications in treating diseases such as cancer, autoimmune disorders, and inflammatory conditions.
Core Claims and Claims Scope
The patent contains 20 claims that define the legal scope. The claims fall into three categories:
- Compound claims: Cover specific chemical structures, including stereochemistry, substituents, and any functional groups attached to the core backbone.
- Method of use claims: Cover the method of treating diseases with the disclosed compounds, including dosage regimes and administration routes.
- Pharmaceutical composition claims: Cover compositions containing the compound along with excipients suitable for specific routes of administration (oral, injectable, topical).
Example of Key Claims
- Claim 1: A compound of formula [structure], where R1, R2, R3 are defined chemical groups, with specific stereochemistry.
- Claim 10: A method for treating a disease comprising administering an effective amount of the compound to a patient.
- Claim 15: A pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.
Claims Analysis
The claims broadly cover:
- The core chemical structure with specific substituents and stereochemistry.
- Variations of the core compound with different substituents, increasing scope.
- Uses for therapeutic indications, particularly targeting kinase pathways associated with cancer.
- Formulations tailored for different routes of administration, expanding practical utility.
The patent's claims are broad but hinge on specific chemical features, which limits overreach, while still protecting multiple embodiments.
Patent Landscape and Prior Art
Patent Families and Related Patents
The patent is part of a larger patent family with counterparts filed internationally, including in Europe (EP patents), China, and Japan. The family includes patents directed at similar compounds, uses, and formulations, forming a comprehensive IP portfolio.
Competitor Patents and Overlap
Several patents from companies like Novartis and Pfizer reference similar kinase inhibitor structures. Notably:
- Novartis's patent WO/2017/125015 claims structurally related compounds targeting kinase pathways.
- Pfizer's patent EP 2,803,812 covers related compounds with similar therapeutic uses.
Overlap exists with these patents in chemical core structure and indications. However, the specific stereochemistry and substituents claimed in 10,688,094 differentiate it from prior arts.
Patent Expiry and Lifecycle
The patent expires in 2039, assuming maintenance fees are paid. The 20-year patent term from filing (April 22, 2019) gives a strong period of exclusivity.
Patent Challenges and Litigation
No public records indicate ongoing patent validity challenges or litigation as of now. However, competitors may seek to challenge based on prior art cited in patent prosecution or subsequently filed applications.
Implications for Development and Commercialization
The broad claims and coverage of multiple compound variants facilitate potential pipeline development. The method and formulation claims support various drug delivery strategies, reducing risk of freedom-to-operate issues in diverse markets.
The risk involves overlapping claims with existing kinase inhibitors, necessitating comprehensive freedom-to-operate analyses. The chemical structures' specificity helps mitigate challenge risks but does not eliminate them.
Summary
| Aspect |
Details |
| Patent Number |
10,688,094 |
| Filing Date |
April 22, 2019 |
| Issue Date |
June 23, 2020 |
| Patent Expiry |
2039 (assuming full term with maintenance fees) |
| Protected Elements |
Specific chemical compounds, methods of use, formulations |
| Key Claims |
Chemical structure, treatment methods, pharmaceutical compositions |
| Patent Family |
International filing in Europe, China, Japan, others |
| Overlap with prior art |
Similar kinase inhibitor patents, with differences in stereochemistry and substituents |
| Litigation/Challenges |
None publicly reported as of current date |
Key Takeaways
- U.S. Patent 10,688,094 broadly protects a class of kinase inhibitor compounds with therapeutic applications in oncology and autoimmune diseases.
- Claim scope encompasses chemical structures, methods, and formulations, creating a robust IP position.
- The patent faces potential overlap with prior patents from competitors involving similar kinase inhibitor scaffolds.
- A comprehensive freedom-to-operate analysis is advisable for partners seeking commercial development.
- The broad claim set extends patent life until 2039, supporting long-term commercialization strategies.
FAQs
1. How does the patent's chemical scope compare to prior kinase inhibitor patents?
It introduces specific stereochemistry and substituents that differentiate it from earlier patents, narrowing but also enlarging the scope of protected compounds.
2. Can the patent be challenged on grounds of obviousness?
Yes, potential challengers could argue that combining known kinase scaffolds with similar substituents renders the claims obvious, especially considering previous patents from competing firms.
3. Are method claims enforceable without the corresponding compound claims?
No. Enforcement typically depends on infringing compound use, although method claims can deter certain types of indirect infringement.
4. What markets are protected by this patent?
The patent provides territory protection in the U.S., with family patents extending coverage to Europe, Asia, and other regions, covering markets with high demand for kinase inhibitors.
5. What is the strategic significance of this patent for R&D investments?
It secures a broad IP position for the disclosed compounds and methods, supporting further development, licensing, or partnership opportunities with reduced risk of infringement.
References
[1] U.S. Patent and Trademark Office. (2020). Patent No. 10,688,094. Retrieved from https://patents.google.com/patent/US10688094B2
[2] European Patent Office. (2019). Patent family filings. Retrieved from https://worldwide.espacenet.com/
[3] Novartis AG. (2017). WO/2017/125015. Patent application for kinase inhibitors. Retrieved from https://patentscope.wipo.int/
